CART therapy moving in a fast-paced market for advanced therapies after collaboration between Kite and Arcellx for multiple myeloma

In this episode, we're giving audiences an update on the latest news of stem cell technologies. The episode highlights the collaboration between a clinical-stage biotech company, Arcellx, and a biopharmaceutical giant, Kite, a Gilead company, on the CART therapy candidate targeting BCMA antigen on multiple myeloma (MM) known as CART-ddBCMA. The candidate is based on a proprietary platform technology D-Domain of Arcellx that aims to improve the efficiency and effective of CART target recognition. Here is more about the candidate in the episode based on the press conference news of Kite and Arcellx.